World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
44
Citations
39092
World Ranking
4733
National Ranking
307

Overview

Jon M. Wigginton is affiliated with Bristol-Myers Squibb in Germany. Their primary research focus lies within the field of medicine, with significant contributions to oncology and immunology. Subfields of study in their work also include general health professions, pulmonary and respiratory medicine, and radiology, nuclear medicine, and imaging.

The scientist's work covers a range of topics primarily centered on cancer immunotherapy and related biomarker research. Key themes in their research include immunotherapy and immune responses, CAR-T cell therapy research, and the management and outcomes of gastric cancer. Additional areas of interest involve esophageal cancer research and treatment, gastrointestinal tumor research and treatment, as well as clinical research related to COVID-19.

Frequent publication venues for Jon M. Wigginton include:

  • Journal of Clinical Oncology
  • Immuno Oncology Insights
  • Value in Health
  • The Lancet Oncology
  • Journal for ImmunoTherapy of Cancer

Some of their recent published papers are:

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023, Journal of Clinical Oncology)
  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial (2020, The Lancet Oncology)
  • The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response (2020, Journal for ImmunoTherapy of Cancer)
  • Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20) (2021, Journal of Clinical Oncology)
  • A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021, Journal of Experimental & Clinical Cancer Research)

Jon M. Wigginton has collaborated frequently with several coauthors, including:

  • Drew M. Pardoll
  • Daniel V.T. Catenacci
  • Yoon-Koo Kang
  • Minori Koshiji Rosales
  • Fernanda I. Arnaldez

Best Publications

  • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

    Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger

  • Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

    Julie R. Brahmer;Scott S. Tykodi;Scott S. Tykodi;Laura Q.M. Chow;Wen Jen Hwu

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • METHOD OF TREATING CANCER USING AN ANTI-PD-1 AND ANTI-CTLA-4 ANTIBODY COMBINATION

    Cogswell John P;Goldberg Stacie M;Gupta Ashok K;Jure-Kunkel Maria

  • Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

    David F. McDermott;Charles G. Drake;Mario Sznol;Toni K. Choueiri

  • Combination immunotherapy: a road map

    Patrick A. Ott;F. Stephen Hodi;Howard L. Kaufman;Jon M. Wigginton

  • The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.

    Jeffrey E Green;Masa-Aki Shibata;Katsuhide Yoshidome;Min-ling Liu

  • Immunotherapy of cancer by IL-12-based cytokine combinations.

    Jonathan M Weiss;Jeff J Subleski;Jon M Wigginton;Robert H Wiltrout

  • Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

    Sacha Gnjatic;Vincenzo Bronte;Laura Rosa Brunet;Marcus O. Butler

  • IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells

    Rosalba Salcedo;Jimmy K. Stauffer;Erin Lincoln;Timothy C. Back

  • Biology of childhood osteogenic sarcoma and potential targets for therapeutic development : Meeting summary

    Richard Gorlick;Peter Anderson;Irene Andrulis;Carola Arndt

  • Administration of Interleukin 12 With Pulse Interleukin 2 and the Rapid and Complete Eradication of Murine Renal Carcinoma

    Jon M. Wigginton;Kristin L. Komschlies;Timothy C. Back;José L. Franco

  • Defining the critical hurdles in cancer immunotherapy

    Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal

  • IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy

    Jon M. Wigginton;Eilene Gruys;Lisa Geiselhart;Jeffrey Subleski

  • Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.

    Daniel V T Catenacci;Yoon-Koo Kang;Haeseong Park;Hope E Uronis

  • Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

    Ilia N. Buhtoiarov;Paul M. Sondel;Jon M. Wigginton;Tatiana N. Buhtoiarova

  • Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow

    Rosalba Salcedo;Julie A. Hixon;Jimmy K. Stauffer;Rashmi Jalah

  • Antitumor activity of interleukin 12 in preclinical models

    M. J. Brunda;Leopoldo Luistro;Leonid Rumennik;Rosemary B. Wright

  • Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

    Unknown

  • Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses

    William J. Murphy;Lisbeth Welniak;Timothy Back;Julie Hixon

Frequent Co-Authors

Robert H. Wiltrout
Robert H. Wiltrout National Institutes of Health
Mario Sznol
Mario Sznol Yale University
Ezio Bonvini
Ezio Bonvini Center for Biologics Evaluation and Research
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Michael B. Atkins
Michael B. Atkins Georgetown University
Charles G. Drake
Charles G. Drake Columbia University
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
Thomas J. Sayers
Thomas J. Sayers Leidos (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with healthcare fields, making nursing a popular adjacent path. For those without a nursing background, there are accessible options such as online absn programs for non nurses that provide a streamlined route into nursing. These programs help build foundational skills quickly, ideal for career changers.

When selecting an accelerated nursing program, many students prioritize entry ease. Programs highlighted under absn programs with high acceptance rates offer greater accessibility, reducing barriers for eager learners aiming to enter the field promptly.

Licensed Practical Nurse (LPN) programs are another viable option for entering healthcare and can serve as stepping stones towards advanced immunology-related studies. Those looking for straightforward enrollment can explore lpn programs easy to get into, which focus on foundational nursing care essential to many medical environments.

Finally, for those pursuing advanced clinical roles, understanding what is the easiest np program is crucial. Nurse practitioner degrees with accessible admission criteria can lead to specialized roles that complement immunology research and patient care.

Best Scientists Citing Jon M. Wigginton

Trending Scientists

Recently Published Articles